- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02734277
Type 1 diabetes extensieonderzoek (T1DES)
This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D).
This observational study will:
- follow participants to determine how long they continue to produce insulin, and
- will also assess how changes in the immune system over time relate to the ability to produce insulin.
This information could help design better therapies for type 1 diabetes in the future.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Depending upon a participant's level of insulin production, participation may be as short as one return visit or a maximum of five years. Evaluation visits will include:
- Overall health assessments
- Blood and urine collections
- Mixed meal tolerance test (MMTTs) for certain participants, per protocol.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studie Locaties
-
-
California
-
San Francisco, California, Verenigde Staten, 94143
- Werving
- UCSF School of Medicine
-
Contact:
- Rebecca Wesch
- Telefoonnummer: 415-476-5984
- E-mail: rebecca.wesch@ucsf.edu
-
Hoofdonderzoeker:
- Stephen Gitelman, MD
-
Stanford, California, Verenigde Staten, 94305
- Werving
- Stanford University
-
Contact:
- Trudy Esrey
- Telefoonnummer: 650-498-4450
- E-mail: tesrey@stanford.edu
-
Hoofdonderzoeker:
- Darrell Wilson, MD
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045
- Werving
- University of Colorado School of Medicine: Barbara Davis Center for Diabetes
-
Hoofdonderzoeker:
- Peter Gottlieb, MD
-
Contact:
- Mara Kinney
- Telefoonnummer: (303) 724-8272
- E-mail: MARA.KINNEY@ucdenver.edu
-
-
Connecticut
-
New Haven, Connecticut, Verenigde Staten, 06519
- Voltooid
- Yale University
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- Ingetrokken
- Emory University
-
-
Indiana
-
Indianapolis, Indiana, Verenigde Staten, 46202
- Werving
- Indiana University Riley Hospital for Children
-
Contact:
- Ellie Ryan
- Telefoonnummer: 317-278-7037
- E-mail: elmryan@iu.edu
-
Contact:
- Maria Spall
- Telefoonnummer: 317-278-7034
- E-mail: malnicho@iu.edu
-
Hoofdonderzoeker:
- Linda DiMeglio, MD, MPH
-
-
Iowa
-
Iowa City, Iowa, Verenigde Staten, 52242
- Werving
- University of Iowa Health Care Division of Pediatric Endocrinology
-
Contact:
- Joanne Cabbage
- Telefoonnummer: 319-356-4035
- E-mail: joanne-cabbage@uiowa.edu
-
Hoofdonderzoeker:
- Michael Tansey, MD
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02215
- Werving
- Joslin Diabetes Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 888-813-8669
- E-mail: T1DTrials@joslin.harvard.edu
-
Hoofdonderzoeker:
- Jason Gaglia, MD
-
-
Minnesota
-
Minneapolis, Minnesota, Verenigde Staten, 55454
- Werving
- University of Minnesota
-
Contact:
- Anne Street
- Telefoonnummer: 612-625-9709
- E-mail: stree065@umn.edu
-
Hoofdonderzoeker:
- Antoinette Moran, MD
-
-
Missouri
-
Kansas City, Missouri, Verenigde Staten, 64108
- Voltooid
- Children's Mercy Hospital
-
-
South Dakota
-
Sioux Falls, South Dakota, Verenigde Staten, 57104
- Voltooid
- Sanford Research
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98101
- Werving
- Benaroya Research Institute
-
Hoofdonderzoeker:
- Sandra Lord, MD
-
Contact:
- Katie Bennett
- Telefoonnummer: (206) 341-8945
- E-mail: kbennett@benaroyaresearch.org
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Former participants in Immune Tolerance Network (ITN) new-onset Type 1 Diabetes Mellitus (T1DM) studies with immunomodulatory agents as the intervention.
Beschrijving
Inclusion Criteria:
- Prior participant in an Immune Tolerance Network (ITN) executive committee approved T1DM study.
- Ability to sign informed consent/assent (as applicable for children).
Exclusion Criteria:
- Any medical condition that in the opinion of the principal investigator would interfere with safe completion of the trial; or
- Inability to comply with the study visit schedule and required assessments.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
|---|
|
Group 1: Detectable C-peptide by MMTT
Participants with detectable C-peptide at their:
Detectable C-peptide is defined as a value above the lower limit of detection. |
|
Group 2:Undetectable C-peptide by MMTT
Participants without detectable C-peptide at their:
Undetectable C-peptide is defined as a value below the lower limit of detection. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Beta Cell Function by MMTT-Stimulated Mean C-peptide Area Under the Curve (AUC)
Tijdsspanne: Baseline (Visit 0) to Month 60 (Year 5)
|
Evaluation of changes in beta cell function over time will be measured by mixed-meal tolerance test (MMTT) -Stimulated mean C-Peptide area under the curve (AUC). C-peptide is released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The standardized MMTT evaluates whether beta cells are producing endogenous insulin. Detectable C-peptide is defined as any value during a MMTT of ≥0.15 ng/mL. |
Baseline (Visit 0) to Month 60 (Year 5)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Insulin Use in Units per Kilogram Body Weight Per Day
Tijdsspanne: Baseline (Visit 0) to Month 60 (Year 5)
|
The need to use exogenous insulin is an indication that the body is not producing enough endogenous insulin. Higher amounts of insulin use indicate higher disease activity. |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Change in HbA1C
Tijdsspanne: Baseline (Visit 0) to Month 60 (Year 5)
|
Glycosylated hemoglobin (HbA1c) is a measure of the average plasma concentration of blood sugar (glucose) over the previous three months and measures the level of optimal management of underlying disease. |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Count of Participant-Reported Major Hypoglycemic Events
Tijdsspanne: Baseline (Visit 0) to Month 60 (Year 5)
|
Major hypoglycemic events are defined as a glucose concentration <55 mg/dL (grades 2-5, NCI-CTCAE version 4.03), or clinically: involving seizure(s) or involving loss of consciousness (coma), or requiring assistance from another individual in order to recover. |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Time to Undetectable C-Peptide
Tijdsspanne: Baseline (Visit 0) to Month 60 (Year 5)
|
To assess the longevity of beta cell function, time to undetectable C-peptide will be evaluated using Kaplan-Meier survival estimates. |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Frequency of Grade 3 or Higher Adverse Events (AEs) of Interest
Tijdsspanne: Baseline (Visit 0) to Month 60 (Year 5)
|
Events of interest include but are not limited to:
Reference for Grade 3 or higher AEs: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03 (June 14, 2010). |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Severity of Grade 3 or Higher Adverse Events (AEs) of Interest
Tijdsspanne: Baseline (Visit 0) to Month 60 (Year 5)
|
Events of interest include but are not limited to:
Reference for Grade 3 or higher AEs: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03 (June 14, 2010). |
Baseline (Visit 0) to Month 60 (Year 5)
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Studie stoel: Linda A. DiMeglio, MD, MPH,MA, Riley Hospital for Children at Indiana University Health
Publicaties en nuttige links
Algemene publicaties
- Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA; AbATE Study Team. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013 Nov;62(11):3766-74. doi: 10.2337/db13-0345. Epub 2013 Jul 8.
- Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015 Aug 3;125(8):3285-96. doi: 10.1172/JCI81722. Epub 2015 Jul 20.
- Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR; T1DAL Study Team. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2013 Dec;1(4):284-94. doi: 10.1016/S2213-8587(13)70111-6. Epub 2013 Sep 23.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Geschat)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- DAIT ITN066AI
- NIAID CRMS ID#: 20722 (Andere identificatie: DAIT NIAID)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
The plan is to share data in: 1.)ImmPort, a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools that are available to researchers who register online and subsequently receive DAIT approval; and 2.)TrialShare, a clinical trials research portal developed by the Immune Tolerance Network that makes data from the consortium's clinical trials publicly available without charge.
IPD-tijdsbestek voor delen
After completion of the study.
IPD-toegangscriteria voor delen
Will be available to the public.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .